CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ChemoCentryx Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ChemoCentryx Inc
835 Industrial Road, Suite 600
Phone: (650) 210-2900p:650 210-2900 SAN CARLOS, CA  94070  United States Fax: (650) 210-2910f:650 210-2910
This company was Merged or Acquired on 10/20/2022.
This company ceased filing statements with the SEC on 10/31/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
ChemoCentryx, Inc. is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. The Company is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The Company's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. It markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Thomas J.Schall 62 4/1/2012 11/1/1997
Chief Financial and Administrative Officer, Executive Vice President, Secretary, Director Susan M.Kanaya 59 1/1/2022 1/1/2006
Chief Operating Officer, Executive Vice President TausifButt 56 2/24/2021 2/24/2021
7 additional Officers and Directors records available in full report.

Business Names
Business Name
CCXI
ChemoCentryx Limited
ChemooCentryx Ireland Limited

General Information
Number of Employees: 178 (As of 12/31/2021)
Outstanding Shares: 71,919,705 (As of 9/13/2022)
Shareholders: 30
Stock Exchange: NASD
Federal Tax Id: 943254365
Fax Number: (650) 210-2910


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, October 25, 2024